MCL-179 TP53 Gene Mutations in Russian Patients With Mantle Cell Lymphoma (MCL)

Bella Biderman,Darya Koroleva,Natalya Severina,Nelly Gabeeva,Hunan Julhakyan,Evgeniy Zvonkov,Andrey Sudarikov

DOI: https://doi.org/10.1016/s2152-2650(23)01374-5

2023-09-01

Abstract:Background TP53 gene mutations are important for the pathogenesis of various human neoplasias. TP53 gene lesions are widely studied in chronic lymphocytic leukemia (CLL), while studies of TP53 mutations in other lymphomas are scarce. Aim To study the frequency, diversity, and significance of TP53 mutations in Russian patients with MCL. Materials and Methods The study included 59 DNA samples from MCL patients. Patients without TP53 mutations received treatment according to the R-BAC/RHA+ auto-HSCT regimen. For the cases with TP53 mutations, enhanced treatment strategies (including various combinations of chemotherapy, targeted therapy, auto- and allo-HSCT, and CAR-T) were used. Mutations in the TP53 gene (exons 4-10) were detected using NGS or Sanger sequencing. The clinical significance of the detected variants was assessed using the Seshat online tool based on the UMD TP53 Mutation Database. Results TP53 gene mutations were detected in 24 patients (40%): 21 cases with missense variants (6 of them in “hotspot” positions – 4 p.R248 and 2 p.R273), 2 patients with splicing site variants, and 1 case with nonsense variant. 20 variants were identified as likely pathogenic, and 4 had unclear significance. Median overall (OS) survival in patients with TP53 mutations was 20 months, while in the group without mutations, the median OS was not reached. In the group with TP53 mutations, 50% of fatal outcomes were associated with disease progression and 50% with other causes. In the group without mutations, 25% of deaths were associated with treatment and disease progression and 75% with other causes. The median OS in patients with TP53 mutations was 20 months, and in the group without mutations, the median OS was not reached. Conclusion The frequency of TP53 gene mutations in our cohort of patients with MCL was significantly higher than the mutation frequency reported in other MCL cohorts. One can explain this bias by patient selection. Our results show that the course of MCL in patients with TP53 mutations is significantly worse despite enhanced treatment protocols. We are planning further studies of the impact of the type of mutations, allelic load, and combinations with other chromosome 17 lesions on the disease course.

oncology,hematology